DK1185659T3 - DNA-vaccine-PCV - Google Patents

DNA-vaccine-PCV

Info

Publication number: DK1185659T3
Authority: DK; Denmark
Prior art keywords: pcv; sub; orf1; orf2; gene
Prior art date: 1999-06-10

Application number

DK00935220T

Other languages

Danish (da)

English (en)

Inventor

Michel Bublot

Jean-Christophe Franc Audonnet

Catherine Elisabeth Charreyre

Jennifer Maria Perez

Original Assignee

Merial Sas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-10

Filing date

2000-06-08

Publication date

2006-07-10

2000-06-08 Application filed by Merial Sas filed Critical Merial Sas

2006-07-10 Application granted granted Critical

2006-07-10 Publication of DK1185659T3 publication Critical patent/DK1185659T3/da

Links

108010041986 DNA Vaccines Proteins 0.000 title 1
229940021995 DNA vaccine Drugs 0.000 title 1
101000833492 Homo sapiens Jouberin Proteins 0.000 abstract 2
101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 abstract 2
102100024407 Jouberin Human genes 0.000 abstract 2
241001504982 Pepper cryptic virus 1 Species 0.000 abstract 2
241001661006 Pepper cryptic virus 2 Species 0.000 abstract 2
101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 abstract 2
101710130262 Probable Vpr-like protein Proteins 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
-1 cationic lipid Chemical class 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 abstract 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
229920002125 Sokalan® Polymers 0.000 abstract 1
125000003277 amino group Chemical group 0.000 abstract 1
229960001631 carbomer Drugs 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
239000013612 plasmid Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biochemistry (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Physics & Mathematics (AREA)
Obesity (AREA)
Oncology (AREA)
Diabetes (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK00935220T 1999-06-10 2000-06-08 DNA-vaccine-PCV DK1185659T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US13835299P	1999-06-10	1999-06-10

Publications (1)

Publication Number	Publication Date
DK1185659T3 true DK1185659T3 (da)	2006-07-10

Family

ID=22481646

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00935220T DK1185659T3 (da)	1999-06-10	2000-06-08	DNA-vaccine-PCV

Country Status (19)

Country	Link
US (1)	US6943152B1 (pl)
EP (1)	EP1185659B1 (pl)
JP (2)	JP4824233B2 (pl)
KR (1)	KR100680924B1 (pl)
CN (1)	CN1289674C (pl)
AT (1)	ATE319832T1 (pl)
AU (1)	AU775375C (pl)
BR (1)	BRPI0011733B1 (pl)
CA (1)	CA2376523A1 (pl)
DE (1)	DE60026515T2 (pl)
DK (1)	DK1185659T3 (pl)
ES (1)	ES2259605T3 (pl)
HU (1)	HUP0201438A3 (pl)
MX (1)	MXPA01012722A (pl)
PL (1)	PL205643B1 (pl)
PT (1)	PT1185659E (pl)
TW (1)	TWI267551B (pl)
WO (1)	WO2000077188A2 (pl)
ZA (1)	ZA200110130B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6517843B1 (en) *	1999-08-31	2003-02-11	Merial	Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US7192594B2 (en) *	1997-10-03	2007-03-20	Merial Limited	Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US20040062775A1 (en)	1997-12-05	2004-04-01	Agence Francaise De Securite Sanitaire Des Aliments	Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr)	1997-12-05	2004-04-09	Ct Nat D Etudes Veterinaires E	Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
FR2804028B1 (fr) *	2000-01-21	2004-06-04	Merial Sas	Vaccins adn ameliores pour animaux de rente
CN1309836C (zh) *	2001-03-27	2007-04-11	萨斯喀彻温大学	培养环状病毒的方法
US7276353B2 (en) *	2001-12-12	2007-10-02	Virginia Tech Intellectual Properties, Inc.	Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) *	2001-12-12	2007-10-09	Virginia Tech Intellectual Properties, Inc.	Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7371395B2 (en) *	2003-07-24	2008-05-13	Merial Limited	Vaccine formulations
WO2005049794A2 (en)	2003-11-13	2005-06-02	University Of Georgia Research Foundation, Inc.	Methods of characterizing infectious bursal disease virus
US7833707B2 (en) *	2004-12-30	2010-11-16	Boehringer Ingelheim Vetmedica, Inc.	Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en)	2005-12-29	2010-04-20	Boehringer Ingelheim Vetmedica, Inc.	PCV2 immunogenic compositions and methods of producing such compositions
HUE025537T2 (en) *	2004-12-30	2016-05-30	Boehringer Ingelheim Vetmedica Inc	PCV2-immunogenic compositions and methods for preparing such compositions
UA95602C2 (ru)	2004-12-30	2011-08-25	Берингер Ингельхейм Ветмедика, Инк.	Иммуногенная композиция цвс2 и способы приготовления такой композиции
CN1328373C (zh) *	2005-04-07	2007-07-25	南京农业大学	猪ⅱ型圆环病毒重组腺病毒
EP1968630B1 (en)	2005-12-29	2018-01-24	Boehringer Ingelheim Vetmedica, Inc.	Multivalent pcv2 immunogenic compositions
MX338626B (es)	2005-12-29	2016-04-26	Boehringer Ingelheim Vetmed	Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
US7862821B2 (en)	2006-06-01	2011-01-04	Merial Limited	Recombinant vaccine against bluetongue virus
EP2859900A1 (en) *	2006-12-11	2015-04-15	Boehringer Ingelheim Vetmedica, Inc.	Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
JP5200223B2 (ja) *	2006-12-15	2013-06-05	ベーリンガーインゲルハイムフェトメディカインコーポレイテッド	Ｐｃｖ２抗原によるブタの処置
EP1941903A1 (en)	2007-01-03	2008-07-09	Boehringer Ingelheim Vetmedica Gmbh	Prophylaxis and treatment of PRDC
EP1958644A1 (en)	2007-02-13	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Prevention and treatment of sub-clinical pcvd
US7829274B2 (en)	2007-09-04	2010-11-09	Boehringer Ingelheim Vetmedica, Inc.	Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009088950A2 (en) *	2007-12-31	2009-07-16	Boehringer Ingelheim Vetmedica, Inc.	Pcv2 orf2 virus like particle with foreign amino acid insertion
KR20100113582A (ko) *	2008-01-23	2010-10-21	베링거잉겔하임베트메디카인코퍼레이티드	Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
US20110033495A1 (en) *	2008-02-15	2011-02-10	Boehringer Ingelheim Vetmedica, Inc.	Methods and compositions for reducing the impact of enteric diseases
AR078253A1 (es)	2009-09-02	2011-10-26	Boehringer Ingelheim Vetmed	Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
UA107940C2 (en) *	2009-09-10	2015-03-10	Merial Ltd	The vaccine composition that includes the saponin-containing adjuvant
TWI442935B (zh)	2010-12-22	2014-07-01	Sbc Virbac Ltd	豬第二型環狀病毒（ＰｏｒｃｉｎｅＣｉｒｃｏｖｉｒｕｓＴｙｐｅ２）、含彼之免疫組合物、檢測套組及其應用
CA2872789C (en)	2012-05-17	2019-09-03	Zoetis Llc	Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
ES2882374T3 (es)	2013-05-08	2021-12-01	Pharmgate Biologics Inc	Vacuna para PCV2 y micoplasma
EP3049106A1 (en)	2013-09-25	2016-08-03	Zoetis Services LLC	Pcv2b divergent vaccine composition and methods of use
US9505808B2 (en)	2013-10-02	2016-11-29	Boehringer Ingelheim Vetmedica, Inc.	PCV2 ORF2 protein variant and virus like particles composed thereof
CN105251000B (zh) *	2014-09-30	2018-12-14	普莱柯生物工程股份有限公司	猪伪狂犬病病毒疫苗组合物及其制备方法和应用
CN107683289B (zh)	2015-01-26	2021-08-06	芝加哥大学	IL13Rα2结合剂和其在癌症治疗中的用途
HK1252427A1 (zh)	2015-05-14	2019-05-24	Boehringer Ingelheim Animal Health USA Inc.	猪环状病毒生产方法和pcv2疫苗
CN110072547B (zh)	2016-12-14	2024-04-30	硕腾服务有限责任公司	断奶前对抗欧洲猪繁殖与呼吸综合征(prrs)病毒株的有效疫苗接种
CN112292149A (zh)	2018-06-11	2021-01-29	法国诗华大药厂	针对猪圆环病毒的疫苗接种
JP7657287B2 (ja)	2020-07-24	2025-04-04	ベーリンガーインゲルハイムアニマルヘルスユーエスエイインコーポレイテッド	組合せブタワクチン

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946787A (en) *	1985-01-07	1990-08-07	Syntex (U.S.A.) Inc.	N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5550289A (en)	1985-01-07	1996-08-27	Syntex (U.S.A.) Inc.	N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
ES2052685T3 (es) *	1987-03-17	1994-07-16	Akzo Nv	Metodo para producir un adyuvante libre.
US5106733A (en)	1987-06-25	1992-04-21	Immunex Corporation	Bovine granulocyte-macrophage colony stimulating factor
CA2489769A1 (en)	1989-03-21	1990-10-04	Philip L. Felgner	Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
WO1992005255A1 (en)	1990-09-13	1992-04-02	Commonwealth Scientific And Industrial Research Organisation	Ovine cytokine genes
AU4662393A (en)	1992-07-08	1994-01-31	Schering Corporation	Use of gm-csf as a vaccine adjuvant
EP0620277A1 (en)	1993-03-18	1994-10-19	Merck & Co. Inc.	Nucleic acid pharmaceuticals
EP1624068A1 (en)	1993-06-01	2006-02-08	Life Technologies Inc.	Genetic immunization with cationic lipids
JP3626187B2 (ja) *	1993-06-07	2005-03-02	バイカルインコーポレイテッド	遺伝子治療に適するプラスミド
US6015686A (en) *	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
EP0804249A2 (en) *	1994-03-15	1997-11-05	Brown University Research Foundation	Polymeric gene delivery system
US5719131A (en)	1994-12-09	1998-02-17	Genzyme Corporation	Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
JPH11504631A (ja)	1995-04-25	1999-04-27	バイカルインコーポレイテッド	Ｄｎａ／脂質複合体の単一バイアル製剤
US5705385A (en)	1995-06-07	1998-01-06	Inex Pharmaceuticals Corporation	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6019980A (en)	1995-06-07	2000-02-01	Connaught Laboratories Limited	Nucleic acid respiratory syncytial virus vaccines
AU729579B2 (en) *	1996-10-23	2001-02-01	Trustees Of The University Of Pennsylvania, The	Immunotherapy and improved vaccines
WO1998040499A1 (en)	1997-03-10	1998-09-17	Heather Lynn Davis	Gene delivery to mucosal epithelium for immunization or therapeutic purposes
FR2781159B1 (fr) *	1998-07-06	2000-10-06	Merial Sas	Vaccin circovirus et parvovirus porcin
US6391314B1 (en)	1997-10-03	2002-05-21	Merial	Porcine circoviruses vaccines diagnostic reagents
UA78180C2 (uk)	1997-10-03	2007-03-15	Меріаль	Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6165493A (en) *	1997-10-22	2000-12-26	New York Blood Center, Inc.	"Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
FR2772047B1 (fr)	1997-12-05	2004-04-09	Ct Nat D Etudes Veterinaires E	Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
JP3795751B2 (ja)	1997-12-11	2006-07-12	ユニバーシティオブサスカッチェワン	ブタからの離乳後多全身系消耗症候群ウイルス
ATE338118T1 (de) *	1997-12-12	2006-09-15	Univ Western Ontario	Neues peptid, apoep1.b, zusammensetzungen und verwendungen davon
EP1064024A4 (en) *	1998-03-13	2005-04-06	Univ Georgia Res Found	VACCINES AGAINST CIRCOVIRUS INFECTIONS
AU1131200A (en)	1998-10-23	2000-05-15	Heska Corporation	Cationic lipid-mediated enhancement of nucleic acid immunization of cats
EP1057891A1 (en) *	1999-06-02	2000-12-06	Centrum Voor Plantenveredelings- En Reproduktieonderzoek	Use of the BNM3 transcriptional activator to control plant embryogenesis and regeneration processes
US6497883B1 (en)	1999-06-10	2002-12-24	Merial	Porcine circovirus recombinant poxvirus vaccine

2000
- 2000-05-31 US US09/586,535 patent/US6943152B1/en not_active Expired - Lifetime
- 2000-06-08 EP EP00935220A patent/EP1185659B1/en not_active Expired - Lifetime
- 2000-06-08 MX MXPA01012722A patent/MXPA01012722A/es active IP Right Grant
- 2000-06-08 DE DE60026515T patent/DE60026515T2/de not_active Expired - Lifetime
- 2000-06-08 BR BRPI0011733A patent/BRPI0011733B1/pt not_active IP Right Cessation
- 2000-06-08 AU AU50786/00A patent/AU775375C/en not_active Expired
- 2000-06-08 PT PT00935220T patent/PT1185659E/pt unknown
- 2000-06-08 DK DK00935220T patent/DK1185659T3/da active
- 2000-06-08 JP JP2001503633A patent/JP4824233B2/ja not_active Expired - Lifetime
- 2000-06-08 WO PCT/EP2000/005611 patent/WO2000077188A2/en not_active Ceased
- 2000-06-08 AT AT00935220T patent/ATE319832T1/de active
- 2000-06-08 HU HU0201438A patent/HUP0201438A3/hu unknown
- 2000-06-08 KR KR1020017015880A patent/KR100680924B1/ko not_active Expired - Lifetime
- 2000-06-08 PL PL352199A patent/PL205643B1/pl unknown
- 2000-06-08 CN CNB008096686A patent/CN1289674C/zh not_active Expired - Lifetime
- 2000-06-08 ES ES00935220T patent/ES2259605T3/es not_active Expired - Lifetime
- 2000-06-08 CA CA002376523A patent/CA2376523A1/en not_active Abandoned
- 2000-06-12 TW TW089111424A patent/TWI267551B/zh not_active IP Right Cessation
2001
- 2001-12-10 ZA ZA200110130A patent/ZA200110130B/xx unknown
2011
- 2011-05-25 JP JP2011116460A patent/JP5410472B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
PT1185659E (pt)	2006-05-31
CA2376523A1 (en)	2000-12-21
PL205643B1 (pl)	2010-05-31
EP1185659B1 (en)	2006-03-08
DE60026515D1 (de)	2006-05-04
TWI267551B (en)	2006-12-01
ZA200110130B (en)	2002-07-15
HUP0201438A3 (en)	2004-07-28
KR100680924B1 (ko)	2007-02-08
MXPA01012722A (es)	2002-07-22
BRPI0011733B1 (pt)	2017-03-28
BR0011733A (pt)	2002-07-23
AU775375C (en)	2005-02-24
CN1289674C (zh)	2006-12-13
AU775375B2 (en)	2004-07-29
JP2003502303A (ja)	2003-01-21
JP5410472B2 (ja)	2014-02-05
EP1185659A2 (en)	2002-03-13
JP4824233B2 (ja)	2011-11-30
PL352199A1 (en)	2003-08-11
US6943152B1 (en)	2005-09-13
CN1376200A (zh)	2002-10-23
WO2000077188A3 (en)	2001-05-31
JP2011207897A (ja)	2011-10-20
KR20020020729A (ko)	2002-03-15
ES2259605T3 (es)	2006-10-16
HUP0201438A2 (en)	2002-08-28
WO2000077188A2 (en)	2000-12-21
ATE319832T1 (de)	2006-03-15
AU5078600A (en)	2001-01-02
DE60026515T2 (de)	2006-11-23

Publication	Publication Date	Title
DK1185659T3 (da)	2006-07-10	DNA-vaccine-PCV
DE69730839T2 (de)	2005-09-29	Hühner polynukleotide impfstoff-formulierung
WO2001092470A3 (en)	2004-03-25	Dna expression vectors and methods of use
CA2305623A1 (fr)	1999-04-15	Circovirus porcins, vaccins et reactifs de diagnostic
CA2448208A1 (en)	2002-12-05	Influenza vaccine composition
DK1030690T3 (da)	2002-10-21	Rekombinante vacciner, der omfatter immunogene svækkede bakterier med RpoS positiv fænotype
UA88457C2 (ru)	2009-10-26	Иммуностимулирующая нуклеиновая кислота с улучшенной иммуностимулирующей эффективностью
MY138978A (en)	2009-08-28	Use of immidazoquinolinamines as adjuvants in dna vaccination
CA2469599A1 (en)	2003-06-19	Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
ES2153223T3 (es)	2001-02-16	Flavivirus quimericos y/o flavivirus de crecimiento restringido.
NZ288026A (en)	1999-11-29	A method for producing influenza hemagglutinin multivalent vaccines
ZA200701043B (en)	2007-12-27	Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
WO2001068129A3 (de)	2002-03-14	Adjuvans für vakzinen
BE857014R (fr)	1978-01-20	Preparation de vaccins a base d'acides nucleiques arn associes a des polysaccharides extraits de germes microbiens.
EP2019140A3 (en)	2009-02-04	Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
WO1995005460A3 (en)	1995-03-23	Feline immunodeficiency virus isolate ncsu 1
ATE481479T1 (de)	2010-10-15	Neue plasmide und deren nutzung
EP0691404A3 (de)	1997-11-12	Verbesserte Vakzine zur Immunisierung gegen TBE-Virusinfektionen sowie ein Verfahren zu dessen Herstellung
BR0002602A (pt)	2001-01-02	Vacina viva atenuada, uso de uma bactéria viva atenuada, e, processo para a preparação de uma vacina
FR2305990A1 (fr)	1976-10-29	Preparation de vaccins a base d'acides nucleiques arn associes a des polysaccharides extraits de germes microbiens
TH45976A (th)	2001-06-29	ดีเอนเอวัคซีน pcv
WO2004020585B1 (en)	2004-10-07	Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
CA2365392A1 (en)	2000-09-08	Vaccine preparation containing fatty acid as a constituent
ATE330969T1 (de)	2006-07-15	Impfstoffe basierend auf mutanten des virus der infektiösen bursal-krankheit
EP2374894A3 (en)	2011-11-09	A method for producing influenza hemagglutinin multivalent vaccines